Healthcare Unfiltered Express

Episode 57: The KOMET-007 Trial

19 min · Ayer
Portada del episodio Episode 57: The KOMET-007 Trial

Descripción

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements.  A must listen - please share subscribe, and join the conversation.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Healthcare Unfiltered Express!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

57 episodios